Evidence map›Paper›PMID 37314737›Full record

ArticleHepatology communications2023

Thermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: A multicenter retrospective comparative study.

Andrew M Moon, Hannah P Kim, Amit G Singal, Dawn Owen, Mishal Mendiratta-Lala, Neehar D Parikh, Steven C Rose, Katrina A McGinty, Chris B Agala, Lauren M Burke and 24 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Microwave ablationJHEP reports : innovation in hepatology · 2025
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 11 institutions in 1 country.

Andrew M MoonDivision of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0001-7163-2062
Hannah P KimDivision of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0001-5518-452
Amit G SingalDivision of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-1172-3971
Dawn OwenDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-0538-3202
Mishal Mendiratta-LalaDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0003-4055-916
Neehar D ParikhDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-5874-9933
Steven C RoseDepartment of Radiology, University of California-San Diego, San Diego, California, USA.
Katrina A McGintyDepartment of Radiology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0001-8707-4958
Chris B AgalaDepartment of Surgery, University of North Carolina, Chapel Hill, North Carolina, USA.
Lauren M BurkeDepartment of Radiology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-1074-5543
Anjelica AbateDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Ersan AltunDepartment of Radiology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-0960-0075
Christian BeyerDivision of Hospital Medicine, Baylor Scott and White Hospital System, Waxahachie, Texas, USA.
John DoDepartment of Radiology, University of California-San Diego, San Diego, California, USA.
Michael R FolkertDepartment of Radiation Medicine, Northwell Health, Lake Success, New York, USA.ORCID 0000-0002-2886-0956
Chalon ForbesDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Jona A Hattangadi-GluthDepartment of Radiation Oncology, University of California-San Diego, San Diego, California, USA.ORCID 0000-0001-8222-606
Paul H HayashiCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.ORCID 0000-0002-5371-1020
Keri JonesDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Gaurav KhatriDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-3485-1650
Yuko KonoDepartment of Radiology, University of California-San Diego, San Diego, California, USA.ORCID 0000-0002-9357-4104
Theodore S LawrenceDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-4186-8821
Christopher MaurinoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
David M MauroDepartment of Radiology, University of North Carolina, Chapel Hill, North Carolina, USA.
Charles S MayoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Taemee PakDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Preethi PatilDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Emily C SandersDivision of Pulmonary, Allergy, and Critical Care Medicine, Duke University, Durham, North Carolina, USA.
Daniel R SimpsonDepartment of Radiation Oncology, University of California-San Diego, San Diego, California, USA.
Joel E TepperLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-8591-4228
Diwash ThapaUniversity of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Ted K YanagiharaDepartment of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina, USA.
Kyle WangDepartment of Radiation Oncology, University of Cincinnati, Cincinnati, Ohio, USA.
David A GerberLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-7972-5228
University of North Carolina at Chapel Hill · USUniversity of Michigan · USUniversity of California San Diego · USThe University of Texas Southwestern Medical Center · USBaylor Scott & White Health · USDuke University · USMayo Clinic · USNorthwell Health · USUnited States Food and Drug Administration · USUniversity of Cincinnati · USVanderbilt University Medical Center · US

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
DIGESTIVE DISEASES EPIDEMIOLOGY TRAINING PROGRAMT32DK007634 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1990 to 2026
$7.4M
NCATS NIH HHS UL1 TR002489NIDDK NIH HHS T32 DK007634
6 · The paper itself

Abstract

BACKGROUND

aimsEarly-stage HCC can be treated with thermal ablation or stereotactic body radiation therapy (SBRT). We retrospectively compared local progression, mortality, and toxicity among patients with HCC treated with ablation or SBRT in a multicenter, US cohort. APPROACH

resultsWe included adult patients with treatment-naïve HCC lesions without vascular invasion treated with thermal ablation or SBRT per individual physician or institutional preference from January 2012 to December 2018. Outcomes included local progression after a 3-month landmark period assessed at the lesion level and overall survival at the patient level. Inverse probability of treatment weighting was used to account for imbalances in treatment groups. The Cox proportional hazard modeling was used to compare progression and overall survival, and logistic regression was used for toxicity. There were 642 patients with 786 lesions (median size: 2.1 cm) treated with ablation or SBRT. In adjusted analyses, SBRT was associated with a reduced risk of local progression compared to ablation (aHR 0.30, 95% CI: 0.15-0.60). However, SBRT-treated patients had an increased risk of liver dysfunction at 3 months (absolute difference 5.5%, aOR 2.31, 95% CI: 1.13-4.73) and death (aHR 2.04, 95% CI: 1.44-2.88, p < 0.0001).

conclusionsIn this multicenter study of patients with HCC, SBRT was associated with a lower risk of local progression compared to thermal ablation but higher all-cause mortality. Survival differences may be attributable to residual confounding, patient selection, or downstream treatments. These retrospective real-world data help guide treatment decisions while demonstrating the need for a prospective clinical trial.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsRadiosurgeryAdultHumansPatient SelectionRetrospective Studies

Identifiers

PMID37314737
PMCPMC10270501
OpenAlexW4380576698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.